These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22238326)

  • 1. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.
    Klapper W; Kreuz M; Kohler CW; Burkhardt B; Szczepanowski M; Salaverria I; Hummel M; Loeffler M; Pellissery S; Woessmann W; Schwänen C; Trümper L; Wessendorf S; Spang R; Hasenclever D; Siebert R;
    Blood; 2012 Feb; 119(8):1882-7. PubMed ID: 22238326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
    Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
    Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
    Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
    Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 14. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
    Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.
    Katzenberger T; Ott G; Klein T; Kalla J; Müller-Hermelink HK; Ott MM
    Am J Pathol; 2004 Aug; 165(2):481-90. PubMed ID: 15277222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N; Bernard V; Feller AC; Merz H
    Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma.
    Palanisamy N; Abou-Elella AA; Chaganti SR; Houldsworth J; Offit K; Louie DC; Terayu-Feldstein J; Cigudosa JC; Rao PH; Sanger WG; Weisenburger DD; Chaganti RS
    Genes Chromosomes Cancer; 2002 Feb; 33(2):114-22. PubMed ID: 11793437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.